



Final Appraisal Recommendation

Advice No: 1216 – May 2016

**Guanfacine (Intuniv[®]▼) 1 mg, 2 mg, 3 mg and 4 mg
prolonged-release tablets**

Submission by Shire Pharmaceuticals Ltd

Recommendation of AWMSG

Guanfacine (Intuniv[®]▼) is not recommended for use within NHS Wales for the treatment of attention deficit hyperactivity disorder (ADHD) in children and adolescents 6 to 17 years old for whom stimulants are not suitable, not tolerated or have been shown to be ineffective.

The case for cost-effectiveness has not been proven.

Key factor(s) influencing the recommendation:

- There are considerable uncertainties and limitations in the economic model provided in the company's submission.
- The applicant company did not present sufficiently robust economic analyses to gain approval by AWMSG.

Additional note(s):

- Patients who are currently being treated with guanfacine (Intuniv[®]▼) for the indication stated above should have the option to continue their therapy until they and their clinicians consider it appropriate to stop.

In reaching the above recommendation AWMSG has taken account of the appraisal documentation prepared by the AWMSG Secretariat (reference number 2361), which includes the AWMSG Secretariat Assessment Report (ASAR), the Preliminary Appraisal Recommendation (PAR) and the applicant company's response to the PAR, clinical expert opinion (where available), the views of patients/patient carers (where available) and the lay member perspective.

This recommendation has been ratified by the Minister for Health and Social Services and will be considered for review every three years.

Statement of use: No part of this recommendation may be reproduced without the whole recommendation being quoted in full and cited as:

All Wales Medicines Strategy Group. Final Appraisal Recommendation – 1216:
Guanfacine (Intuniv[®]▼) 1 mg, 2 mg, 3 mg and 4 mg prolonged-release tablets. May 2016.



NICE has accredited the process used by the All Wales Medicines Strategy Group (AWMSG) to produce its final appraisal recommendation. Accreditation is valid for 5 years from October 2011. More information on accreditation can be viewed at www.evidence.nhs.uk.

For full details on our accreditation visit: www.nice.org.uk/accreditation.